secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001367644-25-000198
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent Q3 revenue $231.1M beats guidance; raises FY2025 revenue & EBITDA view
-------------------------------------------------------------------------------

- Total revenue $231.1M (above Q3 guidance high by $21M); net income $51.2M ($0.91 EPS).
- Adjusted EBITDA $87.8M (38% margin); adjusted EPS $1.06; gross margin expanded 300bps to 54%.
- Naloxone segment down 21% to $74.9M; MCM down 18% to $142.5M; Other Products up 91% to $57.5M.
- FY2025 guidance raised: revenue $775-$835M (from $765-$835M), adjusted EBITDA $195-$210M (from $175-$200M).
- Secured $56M ACAM2000, $52M CNJ-016, $30M CYFENDUS, $29M international MCM contracts in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000198/0001367644-25-000198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000198/ebs-20251029.htm
  HTML page:      https://secwatch.observer/filing/0001367644-25-000198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer